Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: Correlation with time to relapse in patients with resected high-risk disease

Clinical Cancer Research

Volumn 13, Issue 1, 2007, Pages 215-222

  Hamid, Omid ^a   Solomon, Jolie C ^b   Scotland, Ronald ^b   Garcia, Marile ^b   Sian, Shirley ^a   Ye, Wei ^b   Groshen, Susan L ^b   Weber, Jeff S ^b,c  

^a Angeles Clinic and Research Institute   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; FREUND ADJUVANT; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 100 209 217; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; MELAN A; MELAN A 26 35; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE; MONTANIDE ISA 51; TYROSINASE 368 376; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ALLERGY; ARTHRALGIA; ARTICLE; BLURRED VISION; CANCER IMMUNIZATION; CANCER PAIN; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DRUG WITHDRAWAL; EDEMA; ENZYME LINKED IMMUNOSPOT ASSAY; EYE DISEASE; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; LUNG DISEASE; MALE; MELANOMA; MUSCULOSKELETAL DISEASE; MYALGIA; NAUSEA; PRIORITY JOURNAL; PRURITUS; RASH; RIGOR; SIDE EFFECT; SKIN DISEASE; SKIN TEST; SWEATING; THORAX PAIN; TUMOR IMMUNITY; VOMITING;

AGED; ALUM COMPOUNDS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; FEMALE; HUMANS; INTERLEUKIN-12; MALE; MELANOMA; MIDDLE AGED; RECURRENCE; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 33846322927     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1450     Document Type: Article

References (39)

1. Rosenberg SA. Shedding light on immunotherapy for cancer. N Engl J Med 2004;350:1461-3.
2. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002;2:227-38.
3. Rosenberg SA. Identification of cancer antigens: impact on development of cancer immunotherapies. Cancer J 2000;6 Suppl 3:5200-7.
4. Van Der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002;188:51-64.
5. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004;4:1.
6. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003;21:3343-50.
7. Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998;90:1894-900.
8. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. Clin Oncol 2002;20:4169-80.
9. Zajac P, Oertli D, Marti W, et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther 2003;14:1497-510.
10. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 2003;9:2973-80.
11. Donnelly JJ, Wahren B, Liu MA. DNA vaccines progress and challenges. J Immunol 2005;175:633-9.
12. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-7.
13. Lee KH, Wang E, Nielson MB, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1993;163:6292.
14. Marchand M, Van Baren N, Weynants P, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-30.
15. Slingluff CL, Jr., Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-26.
16. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene) - specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004;101:13885-90.
17. Letsch A, Keilholz U, Fluck M, et al. Peptide vaccination after repeated resection of metastases can induce a prolonged relapse-free interval in melanoma patients. Int J Cancer 2005;114:936-41.
18. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827-45.
19. + T cells through IL-12 produced by listeria-induced macrophages. Science 1993;260:547-9.
20. + T cells. J Immunol 1995;154:5071-9.
21. Boyer JD, Cohen AD, Ugen KE, et al. Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids. AIDS 2000;14:1515-22.
22. Salem ML, Kadima AN, Zhou Y, et al. Paracrine release of IL-12 stimulates IFN-γ production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J Immunol 2004;172:5159-67.
23. Nanni P, Nicoletti G, De Giovanni C, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med 2001;194:1195-205.
24. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART1/Melan-A. Cancer J Sci Am 1997;3:37.
25. Pullarkat V, Scotland R, Rubio V, et al. Phase I trial of SD-9427 (Progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res 2003;9:1301-12.
26. Lee P, Wang F, Kuniyoshi J, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001;19:3836-44.
27. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin-12 in patients with advanced malignancies. Clin Cancer Res 1997;3:409-17.
28. Gollob JA, Mier JW, Veenstra K, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin Cancer Res 2000;6:1678-92.
29. Jankovic D, Caspar P, Zweig M, et al. Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J Immunol 1997;159:2409-17.
30. Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999;163:4481-8.
31. Egan MA, Chong SY, Megati S, et al. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses 2005;21:629-43.
32. Stobie L, Gurunathan S, Prussin C, et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge. Proc Natl Acad Sci USA 2000;97:8427-32.
33. Chang J, Cho JH, Lee SW, Choi SY, Ha SJ, Sung YC. IL-12 priming during in vitro antigenic stimulation changes properties of CD8 T cells and increases generation of effector and memory cells. J Immunol 2004;172:2818-26.
34. Portielje JE, Kruit WH, Eerenberg AJ, et al. Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant. Cancer Immunol Immunother 2005;54:37-43.
35. Peterson AC, Harlin H, Gajewski TF. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 2003;21:2342-8.
36. Cebon J, Jager E, Shackleton MJ, et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun 2003;3:7.
37. Slingluff CL, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-26.
38. Slingluff CL, Jr., Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol 2004;22:4474-85.
39. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.